

PATENT PATE

RECEIVE

APR 1 2 2002

TECH CENTER 1600/290

**APPLICANT** 

CAMPBELL, et al.

SERIAL NO

09/973,283

FILED

October 9, 2001

:

METHODS AND COMPOSITIONS FOR MODULATING THE

THE UNITED STATES PATENT AND TRADEMARK OFFICE

IMMUNE SYSTEM OF ANIMALS

Grp./A.U.

TITLE

1614

Conf. No.

5786

Docket No.

P04854US1

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BEFORE MAILING DATE OF EITHER A FINAL ACTION OR NOTICE OF ALLOWANCE (37 C.F.R. § 1.97(c))

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

This information disclosure statement is being filed *before* the mailing date of either a final action under § 1.113 or a notice of allowance under § 1.311, whichever occurs first.

Attached are Forms PTO/SB/08A and 08B (formerly Form PTO-1449) listing the -relevant art known to the applicant herein. Copies of the listed references are enclosed.

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose. Legible copies of all items listed in Forms PTO/SB/08A and 08B (formerly Form PTO-1449) accompany this information statement.

No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the

CERTIFICATE OF MAILING

I hereby certify that the above correspondence was mailed to the Assistant Commissioner for Patents, Washington, D.C. 20231, as First Class mail, postage prepaid, this 25th day of March, 2002.

Edmund J. Sease

knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

It is not believed any fees are due, however, authorization is hereby made to charge any additional fees required by this paper or credit any overpayment to Deposit Account 26-0084. A duplicate of this paper is attached.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. (Notice of January 9, 1992, 1135 O.G. 13-25, at 25.)

Respectfully submitted,

Edmund J. Sease, Reg. No. 24,741

McKEE, VOORHEES & SEASE, P.L.C.

801 Grand Avenue, Suite 3200

Des Moines, Iowa 50309-2721 Phone No. (515) 288-3667

Fax No. (515) 288-1338

**CUSTOMER NO: 22885** 

Attorneys of Record

- pw -



## **COPY OF PAPERS ORIGINALLY FILED**

Form PTO/SA088 (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
Frademark Office: U.S. DEPARTMENT OF COMMERCE

N/K	epthe Prosework Redu	ction Act of 1	995, no persons a	re required to respond to a collection of in	nformation unless it contains a v	alid OMB control number	_
Substi	tute for form 1449	<b>VPTO</b>			Complete if Known		
				Application Number	09/973,283	RECEIM	FD
INFO	RMATION D	ISCLO	SURE	Filing Date	October 9, 2001		
	<b>TEMENT BY</b>			First Named Inventor	CAMPBELL, Joy M.	APR 1 2 7	ከበ2
				Art Unit	1614		102
(U	se as many sheets	as neces	sary)	Examiner Name			
Sheet	1	of	2	Attorney Docket Number	P04854US1	TECHICENTER 16	00/2900

	U.S. PATENT DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	<u>Document Number</u> .  Number - Kind Code <sup>2</sup> (if known	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- 4,096,244	06/20/1978	Newson et al	
		US- 5,575,999	11/19/1996	Yoder, Ralph C.	
		US- 6,004,576	12/21/1999	Weaver, et al.	
	l	US- 6,258,383	07/10/2001	Gohlke et al.	
		US- 2001/0009681	07/26/2001	Gohlke et al.	
		US- 2002/0004073	01/10/2002	Gohlke et al.	
		US-			
		US -			
		US-			
		US-	, ,,,,,		
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figure Appear	T 6
		EP 0 064 210 B1	08/20/1986	Miles Laboratories		
•		WO 99/04804	02/04/1999	Folan, et al		
		JP 61155335 A2	07/15/1986	Green Cross Corp.		
		JP 02104532 A2	04/17/1990	Consiglio Nazi Ricerche		
				1		

Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in

\*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional)... 2 See Kinds of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. 3

Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Substitute for form 1449B/PTO

Examiner

Initials 1

Cite No.

## **COPY OF PAPERS ORIGINALLY FILED**

Form PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE rk Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

## **INFORMATION DISCLOSURE** STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2

**ABSTRACT 769** 

**ABSTRACT 229** 

Se1CIDs.

	Complete if Known RECEIVE
Application Number	09/973,283
Filing Date	October 9, 2001
First Named Inventor	CAMPBELL, Joy M. APR 1 2 2002
Group Art Unit	1614
Examiner Name	TECH CENTER 1600

2900 TEUM UEN Attorney Docket Number P04854US1 OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the T² item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. Campbell, et al., "Use of plasma protein in swine feeds examined", Feedstuffs, The Weekly Newspaper for Agribusiness, Vol. 70, No. 44, October 26, 1998 Touchette, et al., :"Feeding spray-dried plasma decreases the activation of the hypothalamic-pituitaryadrenal axis", J. Anim. Sci. Vol. 78, Suppl. 1/J. Dairy Sci. Vol. 83, Suppl. 1/2000 (page 181) Touchette, et al., "Feeding spray-dried plasma (SDP) alters the immunological response of the weaned pig to a lipopolysaccharide (LPS) challenge", J. Anim. Sci. Vol. 78, Suppl. 1/J. Dairy Sci. Vol. 83, Suppl. 1/2000 (page 43) ABSTRACT 173 Touchette, et al. "Effect of spray-dried plasma and l8popolysaccharide (LPS) on intestinal morphology and the hypothalamic-pituitary-adrenal (HPA) axis of the weaned pig", J. Anim. Sci. Vol. 77, Suppl. 1/J. Dairy Sci. 1/2000 (page 56) ABSTRACT 130 Zannelli, et al., "A comparison of the immunological response to Lipopolysaccharide (LPS) versus E.coli challenge in the weaned pig", J. Anim. Sci. Vol. 77, Suppl. 1/J. Dairy Sci. 1/2000 (page 57)

Evaminas	
Examiner	Date
Signature	Considered

http://www.celgene.com/pharmaceuticals/tnf.htm; 5 pages regarding TNFα Modulation, IMiDs,

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup> EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.